About Nifty Pharma Private Limited
Data last updated: 13 March 2026
Nifty Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 17 December 2007, the company has been in operation for over 19 years.
Registered with ROC Hyderabad under CIN U24232TG2007PTC056705.
Capital: an authorised share capital of ₹3 Cr and a paid-up capital of ₹2.57 Cr. It is led by directors including Desireddy Kesava Reddy and Kota Venkata Reddy.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 1 Satya Sai Residency Beside Mch Park, Hyderabad, Telangana.
As per the financials filed for FY 2024, the company reported a revenue of ₹13.42 Cr, a decline of 7% compared to the previous year.
The company has a workforce of approximately 49 employees as per the latest available data.
The company is associated with 1 brand - Nifty Labs. As per MCA filings, the company has open charges of ₹6.9 Cr and satisfied charges of ₹13.14 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website niftylabs.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressFlat No.203 Plot No.7 – 1 – 54/1 Satya Sai Residency Beside Mch Park Dharam Kharan Road Ame, Erpet, Hyderabad, Telangana, India – 500016
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Nifty Pharma Private Limited
Nifty Pharma Private Limited has one previous CIN (Corporate Identification Number): U24232AP2007PTC056705. The current CIN is U24232TG2007PTC056705, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2007PTC056705 | Current |
| U24232AP2007PTC056705 | Previous |
Associated Brands with Nifty Pharma Private Limited
Nifty Pharma Private Limited operates one associated brand: Nifty Labs. These brands represent Nifty Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Provides comprehensive solutions for API manufacturing and regulatory affairs. | niftylabs.com |
Competitors & Alternatives of Nifty Pharma Private Limited
Brands and companies operating in the same space as Nifty Pharma Private Limited include WuXi AppTec, ANI Pharmaceuticals, Aptar and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
WuXi AppTec
|
Provider of CRO and CDMO services | Shanghai, China, China | 2000 |
ANI Pharmaceuticals
|
Branded and generic prescription drugs are developed, manufactured, and marketed. | Baudette, United States, United States | 1996 |
Aptar
|
Regulatory support, brand differentiation, and prototyping services are provided. | Crystal Lake, United States, United States | 1992 |
CHEPLAPHARM
|
Branded pharmaceutical products are developed, marketed, and distributed globally. | Mesekenhagen, Germany, Germany | 1998 |
Red Nucleus
|
Advisory, scientific, and medical communications provided for pharmaceutical industry. | Yardley, United States, United States | 2014 |
Ipsen
|
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | - | 1929 |
Eurofins Scientific
|
Laboratory testing and contract research services are provided globally. | Luxembourg, Luxembourg, Luxembourg | 1987 |
China Medical System
|
Generic formulations including tablets, capsules, liquids, and injectables are manufactured. | Shenzhen, China, China | 1992 |
Aliada Therapeutics
|
Provider of drug research & development services for multiple therapeutic areas | Boston, United States, United States | 2021 |
Business Activity of Nifty Pharma Private Limited
Nifty Pharma Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Nifty Pharma Private Limited
Nifty Pharma Private Limited is audited by M V NARAYANA REDDY & CO for the financial year 2020. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| M V NARAYANA REDDY & CO | blur-value | blur-value | blur-value |
Board of Directors of Nifty Pharma Private Limited
Nifty Pharma Private Limited is currently managed by 5 directors, with 6 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Desireddy Kesava Reddy
Also directs:
Nifty Labs Private Limited
|
Managing Director | 17 Dec 2007 | 18 Years 6 Months | Current |
| Kota Venkata Reddy | Whole-Time Director | 17 Dec 2007 | 18 Years 6 Months | Current |
|
Krishna Reddy Bhimireddy
Also directs:
Nifty Labs Private Limited, Kondapally Envirotech Private Limited
|
Director | 17 Dec 2007 | 18 Years 6 Months | Current |
|
Bharath Reddy Yerram
Also directs:
Nifty Labs Private Limited
|
Director | 17 Dec 2007 | 18 Years 6 Months | Current |
|
Neha Reddy Desireddy
Also directs:
Nifty Labs Private Limited
|
Additional Director | 19 Nov 2024 | 1 Years 7 Months | Current |
Financials of Nifty Pharma Private Limited FY 2025 filings available
Nifty Pharma Private Limited reported revenue of ₹13.42 Cr (down 7% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Nifty Pharma Private Limited
As of FY 2023, Nifty Pharma Private Limited's shareholding pattern shows 92.98% by promoters, 7.02% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Nifty Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Sep 2025 | Others | ₹6.5 Cr | Open |
| 05 Feb 2025 | Hdfc Bank Limited | ₹40.21 Lakh | Open |
| 12 Jan 2022 | Others | ₹5.45 Cr | Satisfied |
| 11 Aug 2015 | Andhra Pradesh State Financial Corporation | ₹1.5 Cr | Satisfied |
| 13 Sep 2011 | Andhra Pradesh State Financial Corporation | ₹60 Lakh | Satisfied |
Total charge records: 7 View all charges
Employees and EPFO Compliance at Nifty Pharma Private Limited
Nifty Pharma Private Limited has a workforce of 49 employees as of Mar 31, 2024.
Employee Count & EPFO Data of Nifty Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Nifty Pharma Private Limited
GSTIN & GST Filing Data of Nifty Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Nifty Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Nifty Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Nifty Pharma Private Limited
MSME Payment Delays by Nifty Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Nifty Pharma Private Limited
Subsidiaries & Group Companies of Nifty Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Nifty Pharma Private Limited with ownership details.
MCA Filings & Documents of Nifty Pharma Private Limited
MCA Filings & Documents of Nifty Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Nifty Pharma Private Limited
Recent News on Nifty Pharma Private Limited
Frequently Asked Questions about Nifty Pharma Private Limited
Nifty Pharma Private Limited is an active private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 17 December 2007 (19+ years old) and is registered under CIN U24232TG2007PTC056705. The company has 49 employees.
Nifty Pharma Private Limited reported revenue of ₹13.42 Cr for FY 2024 (down 7.00% YoY).
The current directors of Nifty Pharma Private Limited are:
The primary industry of Nifty Pharma Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Nifty Pharma Private Limited can be reached at the registered office: Flat No.203 Plot No.7 – 1 – 541 Satya Sai Residency Beside Mch Park Dharam Kharan Road Ame, Erpet, Hyderabad, Telangana, India – 500016, or through the website niftylabs.com.
The authorised capital is ₹3 Cr, and the paid-up capital is ₹2.57 Cr.